Statin combinations


Published on

Published in: Health & Medicine
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • because the number of particles within any lipoprotein fraction determines the likelihood of any member of that class entering and lodging within an arterial wall
  • for the treatment of elevated LDL-cholesterol levels in patients with primary or mixed hyperlipidemia as an adjunct to dietary changes, as well as for reducing cholesterol levels in patients with homozygous familial hypercholesterolemia
  • Despite theoretic concerns and ex vivo testing suggesting a potential negative interaction with concomitant clopidogrel and CYP3A4-MET statin administration
  • Statin combinations

    1. 1. Statin Combinations Is there a rationale ?
    2. 2. Statin Combinations : A key in search of a lock ! A solution in search of a problem ! • LDLC at goal, but residual risk present. • Statins at optimum dosage, but LDLC not at goal. • Statins taken, but side effects
    3. 3. What is the residual risk due to?
    4. 4. Particle number v/s Lipid level A paradigm to understand • Lipids are carried in lipoprotein particles ( like LDL, IDL, VLDL, Lp(a) etc) • Cholesterol is carried into the arterial wall within a LP particle and … • the number of LP particles determines the likelihood of cholesterol entering and lodging within an arterial wall • Now, the lipid composition of the principal atherogenic lipoproteins differs substantially amongst individuals
    5. 5. For example the amount of cholesterol carried by an LDL particle varies greatly between individuals and can also change in response to lipid altering Rx. A B Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel Report of the thirty person/ten country panel Journal of Internal Medicine, 10 FEB 2006
    6. 6. Particle number v/s Lipid level • Thus, for the same amount of cholesterol measured in 2 individuals, their LP particle number may be different with different degrees of atherogenecity • Therefore, lipid levels do not automatically match lipoprotein particle levels • Hence, the total number of atherogenic particles is a more important determinant of the risk of vascular disease than the level of any of the conventional lipids (TC, TG etc)
    7. 7. Particle number = apo B =non HDLC Clin Lipidol, 2011 Future Medicine Ltd
    8. 8. Atherogenic dyslipidemia: Typical lipid profile of patients with type 2 diabetes and metabolic syndrome Cardiovasc Diabetol, 2012 BioMed Central, Ltd
    9. 9. How to reduce the residual risk of non HDLC ?
    10. 10. ACCORD LIPID study 5518 T2D at high risk for CV events started on Simvastatin at randomization Treatment group fenofibrate added at 1 month- 2765 Placebo group- 2753 Only simvastatin
    11. 11. For the whole group Mean LDL decreased from – 100.0 to 81.1 in Fenofibrate group – 101.1 to 80.0 in placebo group Mean HDL cholesterol levels increased from - 38.0 to 41.2 mg per deciliter in the fenofibrate group - 38.2 to 40.5 mg per deciliter in the placebo group Median plasma triglyceride levels decreased from - 164 to 122 mg per deciliter in the fenofibrate group and - 160 to 144 mg per deciliter in the placebo group.
    12. 12. Bezafibrate • Activates all three PPAR subtypes (alpha, gamma and delta) -> insulin resistance and atherogenic dyslipidemia • Decreases blood glucose level, HbA1C, insulin resistance and reduces the incidence of T2DM compared to placebo or other fibrates. (about 30–40% risk reduction), • Neutralizes the adverse pro-diabetic effect of statins • Significantly decreased prevalence of small, dense low density lipoproteins particles • Has important fibrinogen-related properties and antiinflammatory effects
    13. 13. When to start Fibrates in such selected groups of patients ? • current guidelines recommend treatment for patients with hypertriglyceridemia and low HDL cholesterol levels that persist despite statin therapy • subgroup results of ACCORD and previous trials  from start in patients with type 2 diabetes who have substantial atherogenic dyslipidemia in the basal state
    14. 14. Is HDLC another target ?
    15. 15. However, failed HDLC trials : • AIM HIGH- Niacin • HPS 2 THRIVE - Niacin • Dal-OUTCOMES - dalcetrapib
    16. 16. But HDLC IS important • Vast epidemiological data : low HDL increases the risk of cardiovascular disease by about 40% • Coronary drug project, HATS trial • Meta-analysis of 11 randomized controlled trials, published online December 19, 2012 in the JACC: Treatment with niacin was associated with a significant 34% reduction in the composite end point of any cardiovascular disease event and a significant 25% reduction in coronary heart disease events • Problems with AIM HIGH and HPS 2 THRIVE
    17. 17. Present state of Low HDLC • Check nonHDLC -- Fibrates • Check Lp(a), LDLC ----- Niacin ? • Use non pharmac methods
    18. 18. Effects of Lifestyle Modifications on HDL-C Levels  Weight reduction • For every 3 kg (7 lb) of weight loss, HDL-C levels increase 1 mg/dL  Smoking cessation • HDL-C levels in smokers are 7%–20% lower than those in nonsmokers • HDL-C levels return to normal within 30–60 days after smoking cessation  Exercise • Aerobic exercise (40 min, 3–4 times weekly) increases HDL-C by approximately 2.5 mg/dL
    19. 19. Effect of Drugs on HDL-C Levels Drug Class Effect on HDLC Amount Nicotinic acid 15%–35% Fibrates 10%–15% Estrogens 10%–15% Statins 5%–10% α-Blockers 10%–20% Alcohol 10%
    20. 20. What about Lp(a) ? • Lp(a) is a plasma protein composed of an LDL particle linked to apo(a), which has structural homology with plasminogen. • Lp(a) may therefore contribute to both intimal cholesterol deposition and prothrombotic potential • Genetically determined Lp(a) levels are continuously and linearly related to risk of CVD independent of lifestyle, lipid levels.
    21. 21. When to check for Lp(a) ? • premature cardiovascular disease esp not explained by routine lipid parameters or RF • existing heart or vascular disease, especially with normal or only mildly elevated lipids. • recurrent cardiovascular disease despite statin treatment • family history of premature cardiovascular disease • family history of elevated lipoprotein (a) • familial hypercholesterolaemia, esp low HDL-C • Patients with a moderate or high risk of cardiovascular disease (2010 European Atherosclerosis Society Consensus Panel)
    22. 22. Lp(a) Cut points – Desirable: < 14 mg/dL (< 35 nmol/l) – Borderline risk: 14 - 30 mg/dL (35 - 75 nmol/l) – High risk: 31 - 50 mg/dL (75 - 125 nmol/l) – Very high risk: > 50 mg/dL (> 125 nmol/l) – If the level is elevated, treatment should be initiated with a goal of bringing the level below 50 mg/dL – most studies and meta-analyses show an increase in CVD risk starting at Lp(a) >25 mg/dl
    23. 23. Available Rx for high Lp(a) • Niacin and estrogens lower Lp(a) up to 30% • Aspirin • Statins either have no effect or increase Lp(a) levels Thyromimetics • Cholesterol-ester-transfer protein (CETP inhibitors) • Anti-sense oligonucleopeptides to apoB -Mipomersen • Proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors. • L-carnitine (2 g/day) may also reduce lipoprotein a levels • • Gingko biloba may be beneficial, but has not been clinically verified Coenzyme Q-10 and pine bark extract have been suggested as beneficial, but neither has been proven in clinical trials
    24. 24. Statins at optimum dosage, but LDLC not at goal. Statin combinations with Ezetimibe: • Combo with Atorvastatin- Liptruzet – now FDA approved -2013 • Available as a once-daily tablet containing 10 mg of ezetimibe combined with 10, 20, 40, or 80 mg of atorvastatin.
    25. 25. Outcome studies with Ezetimibe ? • ENHANCE- Simvastatin-Ezetimibe combination (80+20)-Vytorin, did not result in a significant difference in changes in intima-media thickness (IMT) compared with simvastatin alone, despite significantly greater reductions in LDL cholesterol and C-reactive protein • IMPROVE-IT-Outcomes in ACS with ezetimibe/simvastatin combination expected to be completed in 2013 .
    26. 26. Statins at optimum dosage, but LDLC not at goal: Other options o Colesevelam o Niacin, Fibrates o Plant stanols and sterols approximately 2 g/day reduces LDL-C by approximately 10% o Monoclonal antibody to PCSK9 AMG 145 (Amgen) o Lomitapide and mipomersen sodium
    27. 27. Statins taken, but side effects • Statin myopathy (AHA/ACC/NHLBI)  Myalgia: Pain with normal CPK  Myositis: Pain with incerased CPK (1 to10- fold normal)  Rhabdomyolysis: Increased CPK >= 10- fold normal +/- renal disease
    28. 28. Approach to statin intolerance  Start with low doses of more potent statins • Intermittent dosing • Gradual up-titration  Trial of multiple statins Other therapies • Statin + co-enzymes Q10 • Statin + ezetimibe • Bile acid resin + niacin
    29. 29. Statin-Aspirin Combo “REGARDS”: a cross-sectional analysis  • • • • Participants : neither agent (n = 7,718) aspirin only (n = 3,673) statin only (n = 1,898) both agents (n = 3,008)  • • • • Results: Estimated mean CRP was 2.78 mg/L for subjects taking neither 2.73 mg/L with aspirin only 2.29 mg/L with statins only 2.03 mg/L for subjects taking both agents The association was larger among those who had been taking aspirin for >5 years and among participants with self-reported CVD.
    30. 30. Statin-Clopidogrel Combo • A secondary analysis of “CHARISMA” trial: There was no evidence of an interaction clinically with concomitant clopidogrel and CYP3A4-MET statin administration in 10,078 subjects • A single center, small randomized, pharmacodynamic study in Italy : Adding Atorvastatin to Clopidogrel Reduces High On-Treatment Platelet Reactivity-JACC Interv Feb 21, 2013
    31. 31. Conclusion: When & what would I add to a statin ? • When basal TG >200, basal HDLC <35 & non HDLC abN –ath dyslipid : Fibrates (esp Beza for low HDLC) • When HDLC < 30 with abN Lp(a) and not at goal LDLC :Niacin • When LDLC refractory to highest statin dose : Ezitimibe, Colesevelam monoclonal antibody to PCSK9 AMG145 (Amgen) lomitapide and mipomerse n sodium (? Outcome studies) • When myalgia : Co Q
    32. 32. …. When & what would I add to a statin ? • High TG and intolerance to Fibrates : Omega 3 FA • Diabetic retinopathy, PAD ± Ath DysL, statin induced diab : Feno or Bezafibrate • To reduce CRP: Aspirin • To reduce high platelet reactivity : Clopidogrel ?